Upcoming compassionate use programs for two new antiretrovirals will begin this fall.
Schouten
J
J
D000225:Adenine / Q000627:therapeutic use*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D018579:Patient Selection; D011744:Pyrimidinones / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D000068698:Tenofovir
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D011744:Pyrimidinones; D018894:Reverse Transcriptase Inhibitors; D061466:Lopinavir; D000068698:Tenofovir; D000225:Adenine